It has come to the authors’ attention that an incorrect image had been inadvertently included in the paper. The correct version of Fig. 2g is shown corrected as ahead. This correction has not changed the description, interpretation, or the original conclusions of the article. The authors apologize for these errors and any consequent inconvenience to authors and readers.
Fig. 2
miR-934 is encapsulated within CRC cell-derived exosomes. a qPCR analysis of the expression levels of miR-934 in the culture medium (CM) of seven different CRC cell lines and one normal colon cell line. b, c qPCR analysis of the expression levels of miR-934 in the nucleus, cytoplasm, and culture medium (CM) of the HCT-8 and LoVo cell lines. These cell lines showed relatively higher miR-934 expression than other cell lines. d qPCR analysis of the expression levels of miR-934 in the HCT-8 and LoVo cell lines treated with control medium or RNase A (2 mg/mL) alone or in combination with Triton X-100 (0.1%), for 0.5 h. e, f Phenotype analysis of exosomes derived from HCT-8, HT29, LoVo, and Caco-2 cells using electron microscopy (e) and Nano Sight nanoparticle tracking analysis (f). g Western blot analysis was performed to detect typical exosomal biomarkers (TSG101, CD9, and ALIX) in exosomes derived from the above four CRC cell lines. h, i qPCR analysis of miR-934 expression in the CM of HCT-8/LoVo cells depleted of exosomes by GW4869 (an inhibitor of exosome secretion) (h) or by ultracentrifugation (i). j qPCR analysis of the expression levels of miR-934 in HT-29/HCT-8/LoVo/Caco-2-derived exosomes (*p < 0.05; **p < 0.01; ***p < 0.001)
×
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.
Correction to: Tumor-derived exosomal miR-934 induces macrophage M2 polarization to promote liver metastasis of colorectal cancer
verfasst von
Senlin Zhao Yushuai Mi Bingjie Guan Binbin Zheng Ping Wei Yanzi Gu Zhengxiang Zhang Sanjun Cai Ye Xu Xinxiang Li Xuefeng He Xinyang Zhong Guichao Li Zhiyu Chen Dawei Li
Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.
Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.
Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.
Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.
Update Onkologie
Bestellen Sie unseren Fach-Newsletterund bleiben Sie gut informiert.
